An Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry Disease

Trial Profile

An Open-Label Study to Assess the Safety and Effect on Key Biomarkers of Oral RVX000222 in Subjects With Fabry Disease

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Oct 2017

At a glance

  • Drugs Apabetalone (Primary)
  • Indications Fabry's disease
  • Focus Adverse reactions; Biomarker
  • Sponsors Resverlogix Corporation
  • Most Recent Events

    • 20 Oct 2017 Planned End Date changed from 15 Nov 2018 to 15 May 2019.
    • 20 Oct 2017 Planned primary completion date changed from 30 Oct 2018 to 30 Apr 2019.
    • 20 Oct 2017 Planned initiation date changed from 30 Oct 2017 to 30 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top